92 related articles for article (PubMed ID: 16010693)
21. A further mutation of the FGFR2 tyrosine kinase domain in mild Crouzon syndrome.
de Ravel TJ; Taylor IB; Van Oostveldt AJ; Fryns JP; Wilkie AO
Eur J Hum Genet; 2005 Apr; 13(4):503-5. PubMed ID: 15523492
[TBL] [Abstract][Full Text] [Related]
22. Exclusive paternal origin of new mutations in Apert syndrome.
Moloney DM; Slaney SF; Oldridge M; Wall SA; Sahlin P; Stenman G; Wilkie AO
Nat Genet; 1996 May; 13(1):48-53. PubMed ID: 8673103
[TBL] [Abstract][Full Text] [Related]
23. Allelic loss at 10q26 in osteosarcoma in the region of the BUB3 and FGFR2 genes.
Mendoza S; David H; Gaylord GM; Miller CW
Cancer Genet Cytogenet; 2005 Apr; 158(2):142-7. PubMed ID: 15796961
[TBL] [Abstract][Full Text] [Related]
24. Mutation screening in patients with syndromic craniosynostoses indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome.
Lajeunie E; Heuertz S; El Ghouzzi V; Martinovic J; Renier D; Le Merrer M; Bonaventure J
Eur J Hum Genet; 2006 Mar; 14(3):289-98. PubMed ID: 16418739
[TBL] [Abstract][Full Text] [Related]
25. Craniosynostosis with tracheal sleeve: a patient with Pfeiffer syndrome, tracheal sleeve and additional malformations in whom an FGFR2 mutation was found.
Zackai EH; McDonald-McGinn DM; Stolle C; Huff DS
Clin Dysmorphol; 2003 Jul; 12(3):209. PubMed ID: 14564165
[TBL] [Abstract][Full Text] [Related]
26. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans.
Meyers GA; Orlow SJ; Munro IR; Przylepa KA; Jabs EW
Nat Genet; 1995 Dec; 11(4):462-4. PubMed ID: 7493034
[TBL] [Abstract][Full Text] [Related]
27. Gain-of-function amino acid substitutions drive positive selection of FGFR2 mutations in human spermatogonia.
Goriely A; McVean GA; van Pelt AM; O'Rourke AW; Wall SA; de Rooij DG; Wilkie AO
Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6051-6. PubMed ID: 15840724
[TBL] [Abstract][Full Text] [Related]
28. Ligand-independent activation of fibroblast growth factor receptor-2 by carboxyl terminal alterations.
Lorenzi MV; Castagnino P; Chen Q; Chedid M; Miki T
Oncogene; 1997 Aug; 15(7):817-26. PubMed ID: 9266968
[TBL] [Abstract][Full Text] [Related]
29. Development. There's something curious about paternal-age effects.
Crow JF
Science; 2003 Aug; 301(5633):606-7. PubMed ID: 12893932
[No Abstract] [Full Text] [Related]
30. Comparative localization of fibroblast growth factor receptor-1, -2, and -3 mRNAs in the rat brain: in situ hybridization analysis.
Belluardo N; Wu G; Mudo G; Hansson AC; Pettersson R; Fuxe K
J Comp Neurol; 1997 Mar; 379(2):226-46. PubMed ID: 9050787
[TBL] [Abstract][Full Text] [Related]
31. Clinical spectrum of fibroblast growth factor receptor mutations.
Passos-Bueno MR; Wilcox WR; Jabs EW; Sertié AL; Alonso LG; Kitoh H
Hum Mutat; 1999; 14(2):115-25. PubMed ID: 10425034
[TBL] [Abstract][Full Text] [Related]
32. Activating (P253R, C278F) and dominant negative mutations of FGFR2: differential effects on calvarial bone cell proliferation, differentiation, and mineralization.
Ratisoontorn C; Fan GF; McEntee K; Nah HD
Connect Tissue Res; 2003; 44 Suppl 1():292-7. PubMed ID: 12952211
[TBL] [Abstract][Full Text] [Related]
33. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
[TBL] [Abstract][Full Text] [Related]
34. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders.
van Rhijn BW; van Tilborg AA; Lurkin I; Bonaventure J; de Vries A; Thiery JP; van der Kwast TH; Zwarthoff EC; Radvanyi F
Eur J Hum Genet; 2002 Dec; 10(12):819-24. PubMed ID: 12461689
[TBL] [Abstract][Full Text] [Related]
35. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma.
Sibley K; Cuthbert-Heavens D; Knowles MA
Oncogene; 2001 Feb; 20(6):686-91. PubMed ID: 11314002
[TBL] [Abstract][Full Text] [Related]
36. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection.
Rieger-Christ KM; Mourtzinos A; Lee PJ; Zagha RM; Cain J; Silverman M; Libertino JA; Summerhayes IC
Cancer; 2003 Aug; 98(4):737-44. PubMed ID: 12910517
[TBL] [Abstract][Full Text] [Related]
37. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer.
Giri D; Ropiquet F; Ittmann M
Clin Cancer Res; 1999 May; 5(5):1063-71. PubMed ID: 10353739
[TBL] [Abstract][Full Text] [Related]
38. FGFR2 mutation in clinically nonclassifiable autosomal dominant craniosynostosis with pronounced phenotypic variation.
Steinberger D; Reinhartz T; Unsöld R; Müller U
Am J Med Genet; 1996 Dec; 66(1):81-6. PubMed ID: 8957519
[TBL] [Abstract][Full Text] [Related]
39. The Ser252Trp fibroblast growth factor receptor-2 (FGFR-2) mutation induces PKC-independent downregulation of FGFR-2 associated with premature calvaria osteoblast differentiation.
Lemonnier J; Delannoy P; Hott M; Lomri A; Modrowski D; Marie PJ
Exp Cell Res; 2000 Apr; 256(1):158-67. PubMed ID: 10739663
[TBL] [Abstract][Full Text] [Related]
40. Paternal origin of FGFR2 mutations in sporadic cases of Crouzon syndrome and Pfeiffer syndrome.
Glaser RL; Jiang W; Boyadjiev SA; Tran AK; Zachary AA; Van Maldergem L; Johnson D; Walsh S; Oldridge M; Wall SA; Wilkie AO; Jabs EW
Am J Hum Genet; 2000 Mar; 66(3):768-77. PubMed ID: 10712195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
